Manufacturer
GRACURE PHARMACEUTICALS LTD.
Contents
Rosuvastatin Calcium
Indication
Adjunct to diet for the reduction of elevated total cholesterol (total-C), LDL-C, ApoB, total-C & for increasing HDL-C, in hyperlipidemic & dyslipidemic conditions. Reduction of total mortality & risk of major CV events in adults w/ increased risk of atherosclerotic CV disease based on presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia & severe non-familial hypercholesterolaemia); combined (mixed) dyslipidemia (type IIb) homozygous familial hypercholesterolaemia. Adjunctive therapy to diet to slow progression of atherosclerosis in adults as part of a treatment strategy to lower total-C & LDL-C to target levels. Adjunct to diet to reduce total-C, LDL-C & ApoB levels in childn 10-17 yr w/ heterozygous familial hypercholesterolemia.
Instruction
May be taken with or without food.
Drug interaction
Increased INR w/ warfarin. Increased Cmax & AUC w/ gemfibrozil. Increased plasma conc w/ PIs. Decreased plasma conc w/ Al- & Mg hydroxide-containing antacid susp. Decreased AUC & Cmax w/ erythromycin. Severe myositis & myoglobinuria w/ fibrates.
GRACURE PHARMACEUTICALS LTD.
Contents
Rosuvastatin Calcium
Indication
Adjunct to diet for the reduction of elevated total cholesterol (total-C), LDL-C, ApoB, total-C & for increasing HDL-C, in hyperlipidemic & dyslipidemic conditions. Reduction of total mortality & risk of major CV events in adults w/ increased risk of atherosclerotic CV disease based on presence of CV disease risk markers. Primary dysbetalipoproteinemia (type III hyperlipoproteinemia); primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia & severe non-familial hypercholesterolaemia); combined (mixed) dyslipidemia (type IIb) homozygous familial hypercholesterolaemia. Adjunctive therapy to diet to slow progression of atherosclerosis in adults as part of a treatment strategy to lower total-C & LDL-C to target levels. Adjunct to diet to reduce total-C, LDL-C & ApoB levels in childn 10-17 yr w/ heterozygous familial hypercholesterolemia.
Instruction
May be taken with or without food.
Drug interaction
Increased INR w/ warfarin. Increased Cmax & AUC w/ gemfibrozil. Increased plasma conc w/ PIs. Decreased plasma conc w/ Al- & Mg hydroxide-containing antacid susp. Decreased AUC & Cmax w/ erythromycin. Severe myositis & myoglobinuria w/ fibrates.
Inquiry - Vasticure-20 (Rosuvastatin Tablets 20mg)